- Home
- FAAS vs CASI Comparison
FAAS vs CASI Comparison
Compare FAAS & CASI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FAAS
- CASI
- Stock Information
- Founded
- FAAS 2021
- CASI 1991
- Country
- FAAS Indonesia
- CASI China
- Employees
- FAAS N/A
- CASI N/A
- Industry
- FAAS
- CASI Biotechnology: Pharmaceutical Preparations
- Sector
- FAAS
- CASI Health Care
- Exchange
- FAAS NYSE
- CASI Nasdaq
- Market Cap
- FAAS 34.6M
- CASI 33.4M
- IPO Year
- FAAS N/A
- CASI 1996
- Fundamental
- Price
- FAAS $0.25
- CASI $2.13
- Analyst Decision
- FAAS
- CASI Strong Buy
- Analyst Count
- FAAS 0
- CASI 1
- Target Price
- FAAS N/A
- CASI $6.00
- AVG Volume (30 Days)
- FAAS 513.0K
- CASI 9.7K
- Earning Date
- FAAS 01-01-0001
- CASI 03-31-2025
- Dividend Yield
- FAAS N/A
- CASI N/A
- EPS Growth
- FAAS N/A
- CASI N/A
- EPS
- FAAS N/A
- CASI N/A
- Revenue
- FAAS $57,730,593.00
- CASI $28,537,000.00
- Revenue This Year
- FAAS N/A
- CASI N/A
- Revenue Next Year
- FAAS N/A
- CASI $134.79
- P/E Ratio
- FAAS N/A
- CASI N/A
- Revenue Growth
- FAAS 38.16
- CASI N/A
- 52 Week Low
- FAAS $0.23
- CASI $1.90
- 52 Week High
- FAAS $10.63
- CASI $7.67
- Technical
- Relative Strength Index (RSI)
- FAAS 31.53
- CASI 43.69
- Support Level
- FAAS $0.27
- CASI $2.10
- Resistance Level
- FAAS $0.36
- CASI $2.42
- Average True Range (ATR)
- FAAS 0.06
- CASI 0.23
- MACD
- FAAS -0.01
- CASI -0.00
- Stochastic Oscillator
- FAAS 5.97
- CASI 36.29
About FAAS DIGIASIA CORP
DigiAsia Corp operates as a holding company. The majority of DigiAsia's operations are currently conducted through its majority-owned entities, controlled entities and corporate joint venture. It is among the first embedded fintech as a service (EFaaS) companies in Indonesia serving business-to-business-to-consumer (B2B2C) customers, such as large corporations and state-owned enterprises, as well as business-to-business (B2B) customers, such as micro, small and medium-sized enterprise (MSME) merchants, across various segments. It aims to be a fintech-enabling platform in Southeast Asia by accelerating financial inclusion through its licenses and technology stack and combining the benefits of technological innovation with traditional financial services.
About CASI CASI Pharmaceuticals Inc.
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.